Skip to content

To prospectively explore the safety and efficacy of neoadjuvant chemoembolization in the treatment of breast cancer

To prospectively explore the safety and efficacy of neoadjuvant chemoembolization in the treatment of breast cancer

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000041001
Enrollment
Unknown
Registered
2020-12-16
Start date
2020-12-17
Completion date
Unknown
Last updated
2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

observation group:drug-loaded microsphere embolization+Conventional intravenous chemotherapy
Control group:Conventional intravenous chemotherapy

Sponsors

People's Hospital of Jianyang City, Sichuan Province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-75 years, males or females; 2. Newly diagnosed patients with unresectable breast cancer or patients who want to down-staging and conserve their breast confirmed by histopathological or clinical diagnosis; 3. ECOG <= 2; 4. The pregnancy test for women of childbearing age must be negative or the patients must agree to use effective contraception during the treatment period and within 1 year thereafter.

Exclusion criteria

Exclusion criteria: 1. The breast cancers that can be surgically removed; 2. The patienta with poor coagulation function, INR > 1.5, or are receiving anticoagulant therapy or suffering known hemorrhagic disease; 3. The patients with unstable coronary heart disease or recent myocardial infarction (within one year); 4. Antibiotics are needed for patients with recent infection; 5. WBC 2mg / L); 7. AST and / or ALT > 3 x ULN; 8. There are comorbidities or social environment that can cause the subjects to fail to follow the research plan or even endanger the safety of patients; 9. The patient was accompanied with other primary tumors.

Design outcomes

Primary

MeasureTime frame
ORR;PCR;tumor necrosis rate;

Secondary

MeasureTime frame
Improvement of quality of life;adverse reactions;

Countries

China

Contacts

Public ContactJingjun Zhang

People's Hospital of Jianyang City, Sichuan Province

11914746@qq.com+86 13778990563

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026